US 12,344,641 B2
Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof
Steven G. Reed, Bellevue, WA (US); Rhea N. Coler, Seattle, WA (US); Gregory C. Ireton, Seattle, WA (US); and Sylvie Bertholet, Gaithersburg, MD (US)
Assigned to ACCESS TO ADVANCED HEALTH INSTITUTE, Seattle, WA (US)
Filed by ACCESS TO ADVANCED HEALTH INSTITUTE, Seattle, WA (US)
Filed on Jan. 8, 2024, as Appl. No. 18/407,367.
Application 18/407,367 is a division of application No. 17/367,812, filed on Jul. 6, 2021, granted, now 11,897,922.
Application 17/367,812 is a division of application No. 15/815,512, filed on Nov. 16, 2017, granted, now 11,091,521, issued on Aug. 17, 2021.
Application 15/815,512 is a division of application No. 13/791,511, filed on Mar. 8, 2013, granted, now 9,822,152, issued on Nov. 21, 2017.
Application 13/791,511 is a continuation of application No. 12/594,806, granted, now 8,486,414, issued on Jul. 16, 2013, previously published as PCT/US2008/059500, filed on Apr. 4, 2008.
Claims priority of provisional application 60/910,169, filed on Apr. 4, 2007.
Prior Publication US 2024/0140997 A1, May 2, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/35 (2006.01); A61K 39/00 (2006.01); A61K 39/04 (2006.01); C07K 14/285 (2006.01); G01N 33/569 (2006.01); G01N 33/68 (2006.01)
CPC C07K 14/35 (2013.01) [A61K 39/04 (2013.01); C07K 14/285 (2013.01); G01N 33/5695 (2013.01); G01N 33/68 (2013.01); A61K 2039/55561 (2013.01); C07K 2319/00 (2013.01); G01N 2469/20 (2013.01); Y02A 50/30 (2018.01)] 15 Claims
 
1. A method for stimulating an immune response comprising:
administering to a subject an effective amount of a composition comprising two or more Mycobacterium tuberculosis antigens,
wherein the two or more antigens comprise the antigen Rv3478 comprising the amino acid sequence set forth in SEQ ID NO:41 and the antigen Rv3619 comprising the amino acid sequence set forth in SEQ ID NO:46, or
an antigen comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 41 and an antigen comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 46; and
wherein the two or more antigens are covalently linked in the form of a fusion polypeptide.